On the basis of evidence supporting its safety, effectiveness and cost-effectiveness, the supporting committee for this application recommends that Sm-153-lexidronam be subsidised for the relief of bone pain in patients with skeletal metastases (as indicated by a positive bone scan) from the following malignancies:
i. carcinoma of the prostate, where hormonal therapy has failed; or
ii. carcinoma of the breast, where hormonal therapy and chemotherapy have failed; and either:
a. the disease is poorly controlled by conventional radiotherapy; or
b. conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain.